High OCT4 Expression Might Be Associated with an Aggressive Phenotype in Rectal Cancer
- PMID: 37509401
- PMCID: PMC10378144
- DOI: 10.3390/cancers15143740
High OCT4 Expression Might Be Associated with an Aggressive Phenotype in Rectal Cancer
Abstract
Rectal cancer (RC) is one of the most common malignant neoplasms, and cancer stem cells (CSCs) of the intestinal tract have been implicated in its origin. The oncofetal protein OCT4 has been linked to neoplastic processes, but its role and clinical significance in RC are unknown. This study investigates the expression of the stem cell marker OCT4 related to clinical-pathological characteristics and its clinical significance in RC patients. The expression level of stem cell marker OCT4 was analyzed in 22 primary rectal tumors by western blot. The association between OCT4 protein expression and the clinical-pathological features of tumors was evaluated by χ2 test and Fisher's exact test. We demonstrated that the expression of the stem cell marker OCT4 was observed in tumor tissue but not adjacent non-tumor tissue. High expression of the stem cell marker OCT4 was significantly associated with histological differentiation grade (p = 0.039), tumor invasion level (p = 0.004), lymph node involvement (p = 0.044), tumor-node-metastasis (TNM) stage (p = 0.002), and clinical stage (p = 0.021). These findings suggest that high OCT4 expression is associated with a more aggressive RC phenotype, with a greater likelihood of progression and metastasis. These results shed light on the importance of targeting this CSC marker to attenuate RC progression.
Keywords: OCT4; cancer stem cells; colorectal cancer; oncofetal protein; rectal cancer.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures


Similar articles
-
CEA-delta could be a biomarker of tumor phenotype, clinical stage, and chemotherapeutic response in rectal cancer with OCT4-positive cancer stem cells.Front Oncol. 2023 Sep 7;13:1258863. doi: 10.3389/fonc.2023.1258863. eCollection 2023. Front Oncol. 2023. PMID: 37746252 Free PMC article.
-
Correlation of Cancer Stem-Cell Markers OCT4, SOX2, and NANOG with Clinicopathological Features and Prognosis in Operative Patients with Rectal Cancer.Yonsei Med J. 2018 Jan;59(1):35-42. doi: 10.3349/ymj.2018.59.1.35. Yonsei Med J. 2018. PMID: 29214774 Free PMC article.
-
Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients.Mol Cell Oncol. 2020 Jul 14;7(5):1788366. doi: 10.1080/23723556.2020.1788366. eCollection 2020. Mol Cell Oncol. 2020. PMID: 32944642 Free PMC article.
-
Prognostic value of OCT4 in colorectal cancer: analysis using immunohistochemistry and bioinformatics validation.Biomark Med. 2020 Oct;14(15):1473-1484. doi: 10.2217/bmm-2020-0069. Epub 2020 Oct 14. Biomark Med. 2020. PMID: 33185466 Review.
-
Role of OCT4 in cancer stem-like cells and chemotherapy resistance.Biochim Biophys Acta Mol Basis Dis. 2020 Apr 1;1866(4):165432. doi: 10.1016/j.bbadis.2019.03.005. Epub 2019 Mar 21. Biochim Biophys Acta Mol Basis Dis. 2020. PMID: 30904611 Free PMC article. Review.
Cited by
-
CEA-delta could be a biomarker of tumor phenotype, clinical stage, and chemotherapeutic response in rectal cancer with OCT4-positive cancer stem cells.Front Oncol. 2023 Sep 7;13:1258863. doi: 10.3389/fonc.2023.1258863. eCollection 2023. Front Oncol. 2023. PMID: 37746252 Free PMC article.
-
Interconversion of Cancer Cells and Induced Pluripotent Stem Cells.Cells. 2024 Jan 10;13(2):125. doi: 10.3390/cells13020125. Cells. 2024. PMID: 38247819 Free PMC article. Review.
-
Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate Cancer.Biomedicines. 2025 Jul 4;13(7):1642. doi: 10.3390/biomedicines13071642. Biomedicines. 2025. PMID: 40722714 Free PMC article. Review.
References
-
- Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I., Bray F. Global Cancer Observatory (GLOBOCAN): Cancer Today. [(accessed on 19 April 2022)]. Available online: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-she....
-
- Paschke S., Jafarov S., Staib L., Kreuser E.D., Maulbecker-Armstrong C., Roitman M., Holm T., Harris C.C., Link K.H., Kornmann M. Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer. Int. J. Mol. Sci. 2018;19:2577. doi: 10.3390/ijms19092577. - DOI - PMC - PubMed
-
- Zhao X., Han P., Zhang L., Ma J., Dong F., Zang L., He Z., Zheng M. Prolonged neoadjuvant chemotherapy without radiation versus total neoadjuvant therapy for locally advanced rectal cancer: A propensity score matched study. Front. Oncol. 2022;12:953790. doi: 10.3389/fonc.2022.953790. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources